Pluristem up Over 10% After Announcing Agreement with United Therapeutics Corporation

Pluristem Ltd. PSTI entered into an Exclusive License Agreement with United Therapeutics Corporation, for the use of Pluristem's PLacental eXpanded cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension. Under the terms of the Agreement, United Therapeutics will receive exclusive worldwide license rights for development and the commercialization of the PLX-based product in the Field. In addition, in the event that United Therapeutics and Pluristem develop a tissue-engineered product based on PLX to replace lung function, United Therapeutics shall receive a first right to negotiate the use of such product outside the Field. Pluristem will hold manufacturing rights for the developed product, except for certain events of failure to supply where United Therapeutics would then have the right to manufacture the developed product for use in the Field. Pursuant to the terms of the Agreement, Pluristem is eligible to receive aggregate payments of up to approximately $55 million, to be paid by United Therapeutics.